Summary
But this one, for Lillys first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days before, rival pharma giant Pfizer had announced it was abandoning its oral weight-loss drug after worrying side effects involving liver problems were reported in one participant in the trial.
Source: TIME on MSN.com
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
